NCT02034500View on ClinicalTrials.gov

Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Shigellosis
Interventions
BIOLOGICAL

S. sonnei 1790GAHB

BIOLOGICAL

Placebo

Trial Locations (1)

GU2 7XP

Surrey Clinical Research Center (Surrey CRC), Guildford

All Listed Sponsors
lead

GSK Vaccines Institute For Global Health S.r.l.

INDUSTRY

NCT02034500 - Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults | Biotech Hunter | Biotech Hunter